Generated by AI
MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases. MeiraGTx Holdings plc uses a vertically integrated model that combines discovery, development, and manufacturing capabilities to support its genetic medicine programs. Its current pipeline targets conditions in the eye, salivary gland, and central nervous system, including retinal disorders, radiation-induced xerostomia, and Parkinson’s disease. The company’s work centers on local delivery of small doses designed to produce disease-modifying effects in areas of high unmet medical need. MeiraGTx Holdings plc operates as part of the biotechnology and health technology market, where it contributes to the advancement of precision therapies built around genetic intervention.
Website655 Third Avenue
New York, NY, 10017
United States
The latest articles about MGTX.
Summary of Jul 23's posts. Generated by AI.
No summary yet.
Summary of Nov 10's posts. Generated by AI.
Summary of Jul 3's posts. Generated by AI.
Summary of Jul 23's posts. Generated by AI.
Investors talking about MGTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.